Mynarek Martin, Pizer Barry, Dufour Christelle, van Vuurden Dannis, Garami Miklos, Massimino Maura, Fangusaro Jason, Davidson Tom, Gil-da-Costa Maria Joao, Sterba Jaroslav, Benesch Martin, Gerber Nicolas, Juhnke B Ole, Kwiecien Robert, Pietsch Torsten, Kool Marcel, Clifford Steve, Ellison David W, Giangaspero Felice, Wesseling Pieter, Gilles Floyd, Gottardo Nicholas, Finlay Jonathan L, Rutkowski Stefan, von Hoff Katja
Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Oncology Unit, Alder Hey Children's Hospital, Liverpool, UK.
Neuro Oncol. 2017 Apr 1;19(4):576-585. doi: 10.1093/neuonc/now234.
Pineoblastoma is a rare pineal region brain tumor. Treatment strategies have reflected those for other malignant embryonal brain tumors.
Original prospective treatment and outcome data from international trial groups were pooled. Cox regression models were developed considering treatment elements as time-dependent covariates.
Data on 135 patients with pineoblastoma aged 0.01-20.7 (median 4.9) years were analyzed. Median observation time was 7.3 years. Favorable prognostic factors were age ≥4 years (hazard ratio [HR] for progression-free survival [PFS] 0.270, P < .001) and administration of radiotherapy (HR for PFS 0.282, P < .001). Metastatic disease (HR for PFS 2.015, P = .006), but not postoperative residual tumor, was associated with unfavorable prognosis. In 57 patients <4 years old, 5-year PFS/overall survival (OS) were 11 ± 4%/12 ± 4%. Two patients survived after chemotherapy only, while 3 of 16 treated with craniospinal irradiation (CSI) with boost, and 3 of 5 treated with high-dose chemotherapy (HDCT) and local radiotherapy survived. In 78 patients aged ≥4 years, PFS/OS were 72 ± 7%/73 ± 7% for patients without metastases, and 50 ± 10%/55 ± 10% with metastases. Seventy-three patients received radiotherapy (48 conventionally fractionated CSI, median dose 35.0 [18.0-45.0] Gy, 19 hyperfractionated CSI, 6 local radiotherapy), with (n = 68) or without (n = 6) chemotherapy. The treatment sequence had no impact; application of HDCT had weak impact on survival in older patients.
Survival is poor in young children treated without radiotherapy. In these patients, combination of HDCT and local radiotherapy may warrant further evaluation in the absence of more specific or targeted treatments. CSI combined with chemotherapy is effective for older non-metastatic patients.
松果体母细胞瘤是一种罕见的松果体区脑肿瘤。治疗策略与其他恶性胚胎性脑肿瘤的治疗策略相似。
汇总国际试验组的原始前瞻性治疗及结果数据。将治疗因素视为时间依赖性协变量,建立Cox回归模型。
分析了135例年龄在0.01 - 20.7岁(中位年龄4.9岁)的松果体母细胞瘤患者的数据。中位观察时间为7.3年。有利的预后因素为年龄≥4岁(无进展生存期[PFS]的风险比[HR]为0.270,P <.001)和接受放疗(PFS的HR为0.282,P <.001)。转移性疾病(PFS的HR为2.015,P =.006)而非术后残留肿瘤与不良预后相关。在57例年龄<4岁的患者中,5年PFS/总生存期(OS)分别为11±4%/12±4%。仅2例患者单纯化疗后存活,而16例接受全脑全脊髓照射(CSI)加量治疗的患者中有3例存活,5例接受高剂量化疗(HDCT)和局部放疗的患者中有3例存活。在78例年龄≥4岁的患者中,无转移患者的PFS/OS为72±7%/73±7%,有转移患者的PFS/OS为50±10%/55±10%。73例患者接受了放疗(48例为常规分割CSI,中位剂量35.0 [18.0 - 45.0] Gy,19例为超分割CSI,6例为局部放疗),其中68例联合化疗,6例未联合化疗。治疗顺序无影响;HDCT的应用对老年患者的生存影响较弱。
未接受放疗的幼儿生存率较低。在这些患者中,在缺乏更特异或靶向治疗的情况下,HDCT与局部放疗联合可能值得进一步评估。CSI联合化疗对年龄较大的非转移性患者有效。